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membrane. Alternatively, the different patterns could be
due to physical differences in individual virions such as
those that determine the ability of a virion to cause
hemolysis (8).
In summary, Sendai virus can fuse with liposomes
containing only PC, cholesterol, and gangliosides. This
suggests that gangliosides may have a role in membrane
fusion in addition to their receptor function. In liposomes
of this simple composition, the course of disassembly is
variable.
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HUMAN BLOOD PLATELET AGGREGATION-INHIBITORY
TARGET SITES ASSUMED TO INVOLVE MEMBRANE
PHOSPHOLIPIDS
R. P. QUINTANA, A. LASSLO, AND M. DUGDALE,
Departments ofMedicinal Chemistry and Medicine, University of Tennessee Centerfor the Health
Sciences, Memphis, Tennessee 38163 U.S.A.
In an extensive study identifying structural features asso-
ciated with the inhibition of adhesion-release-aggregation
chain reactions in human blood platelets, we employed a
series of carbamoylpiperidine derivatives with systematic
and gradual changes in their molecular constitution,
allowing meaningful interpretation of biological response
variances. Current indications are that the entities concep-
tualized and synthesized in our laboratories (1-6) inhibit
platelet aggregation (culminating at 5 AM concentrations)
by penetrating the lipid bilayer of the platelet membrane
and by interacting, as cations, with negatively charged
phospholipids (e.g., phosphatidylserine and phosphatidyli-
nositol) within the bilayer's inner segment (7). Following
such penetration, those cations could be interfering with
phospholipase-A2 activation by counteracting stimulus-
induced mobilization of Ca"+ ions and Ca"+-dependent
phospholipase-A2 activity (8), thereby rendering platelets
less susceptible to aggregation reactions. Our studies,
employing our mono- and bis(carbamoylpiperidino)al-
kanes and -aralkanes as molecular probes, suggest platelet
aggregation-inhibitory target sites spaced at 8 A, and yield
exacting information on the influence of hydrophobicity,
planarity and geometric isomerism, as well as on the
significance of interatomic distances between, and the
Please address correspondence to Dr. Lasslo.
charge levels of, the amino functions primarily instrumen-
tal in consummating interactions leading to the inhibition
of human blood platelet aggregation.
To confirm these interpretations, the effects of our
carbamoylpiperidine derivatives are being evaluated at
surface pressures estimated to occur in actual platelet
membranes (34 mN m-')(9), on monomolecular films of
phosphatidylserine whose location in the inner segment of
the platelet membrane's lipid bilayer is acknowledged, on
those of phosphatidylcholine, which is known to be a
constituent of the bilayer's outer leaflet, and on related
pure and mixed monolayer systems; e.g., cholesterol/
phospholipid in ratios of 0.5, paralleling those observed in
platelet membranes (10).
MATERIALS AND METHODS
A Payton aggregometer (Payton Associates Inc., Buffalo, NY) with a
dual channel recorder (PFIOHO-D) and a Coulter counter ZBI (Coulter
Electronics Inc., Hialeah, FL) were employed in our platelet aggregation
determinations ( 11); the inhibitory potency of our compounds was
classified: 0 < 10%, 1 + = 1 I-19%, 2+ = 20%-29%, 3+ = 30%-39%,
4+ = 40%-49%, 5 + = 50%-59%, 6 +± 60%. Interfacial and surface
tension values were determined (12) on a Kahlsico duNouy instrument
TE03 (Kahl Scientific Instrument Corp., El Cajon, CA). Surface pres-
sure and potential measurements (13) are being carried out in a recent
version of our previously conceptualized (14) Wilhelmy-type surface
balance system, equipped with a dual pen Omniscribe B-5000 (Houston
Instrument Div., Bausch and Lomb Inc., Austin, TX).
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FIGURE 1 Influence of surface activity
RESULTS AND DISCUSSION
Among the highlights reported here, compounds I and II
(Fig. 1) are equally active. From this and findings
discussed later in this paper we conclude that the distance
between the ring nitrogens separated by a hexamethylene
link (C6) matches closely that of the target sites on the
platelet. The ring nitrogens on the decamethylene chain
(CI0), through appropriate buckling of that flexible link,
can also connect readily with the same target sites. Howev-
er, because the ring nitrogens of the bis-dialkylcarbamoyl-
piperidino-substituted ethane separated by merely two
methylene groups (C2) could not accommodate a compa-
rable reach, this analogue is 10 times weaker (1 + at 100
,uM). In contrast, the mono-substituted decane (III) is
twice as potent as the hexane (IV) (Fig. 1); the hydro-
phobic bonding of the former (C10) on the platelet surface
adjacent to the target site is so strong that it substantially
augments the interaction of its single piperidino nitrogen
with one target site; conversely, in the mono-substituted
hexane, the shorter alkyl chain (C6) is unable to exert
hydrophobic bonding of comparable magnitude. Not
surprisingly, such hydrophobic forces are not discernible at
all in the mono-substituted ethane (C2) which does not
register any activity at these concentrations (0 at 100 .tM).
While the contribution of lipophilicity to enhanced
aggregation-inhibitory potency is evident, our results also
indicate that our bis-substituted derivatives interact with
two target sites on the platelet whenever the polymethy-
lene chain is long enough to accommodate such inter-
course. This is materially substantiated by the relative
potencies of the bis(dialkylcarbamoylpiperidino)xylene
analogues (Fig. 2). Interestingly, the para-congener (VI)
can be envisioned as a close but substantially more potent
(2+ at 5 juM) analogue of the bis-substituted hexane (II,
Fig. 1), in which four of the six methylene units have been
replaced by a phenylene moiety; while this should not
perceptibly affect the hydrophobic character (15) of the
molecule, the planarity of the ring structure renders VI
much more rigid (16a) than II. Conformingly, the intra-
molecular distances between the ring nitrogens, computed
with Godfrey space-filling models, register for the former
a range of 7.8-8.3 A with a flexibility variance of 0.5 A,
and for the latter a range of 4.4-9.1 A with a flexibility
variance of 4.7 A. We suppose that II, in which the range
of ring nitrogen distances encompasses those of VI, is less
active due to the almost 10-fold greater flexibility vari-
ance. Remarkably, the mono-substituted analogue of VI is
only half as active (1+) at 20 times higher concentrations
(100 AuM). The significance of the interatomic distance
between the ring nitrogens in the bis-substituted
compounds is further emphasized by the decreasing activi-
ties of the correspondingly substituted meta-xylene (VII,
5.3-7.8 A, 3 + at 50 ,uM) and ortho-xylene (VIII, 4.8-5.9
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A, 0 at 50SuM) analogues (Fig. 2). These data distinctly
imply platelet membrane target sites spaced at 8 A.
Despite the striking potency of VI, its bis(dialkylcarba-
moylpyridinium) congener (V, Fig. 2) is completely inac-
tive even at 20 times higher concentrations (0 at 100 AM);
this and parallel findings with other comparable analogues
could be attributed either to the aromatic character of the
ring structure and its conjugation with the amide function
(16b), or to the charge level of the ring nitrogen, or to
both. Each factor individually, or both in combination,
could lessen hydrophobicity and reduce aggregation-inhib-
itory potency. As quaternary amines, the heterocyclic
nitrogens in V retain the same charge regardless of their
environment and consequently, in a biosystem, their
hydrophobicity does not even approximate that of corre-
sponding tertiary amines (17, 18), which are generally
subject to broad variances in protonation, contingent upon
the pH of the medium and the specific compounds' pKa
values (6). This very trait of tertiary amines provides
appropriate hydrophobic character for their penetration of
the platelet membrane's lipid bilayer without interfering
with the subsequent generation of adequate cationic
species (19-21). The influence of this parameter is being
examined in greater detail.
The impact of stereoisomerism is delineated in Fig. 3.
The greater potency of the trans-isomer (IX) can also be
attributed to the fact that the intramolecular distance of
its ring nitrogens (5.9-6.3 A) is closer to the postulated
optimum of 8 A than the lesser one computed for the rings'
hetero-atoms in the cis-compound (XI, 5.4-6.1 A). The
increased polarity effected by unsaturation in the alkyl
chain contributes considerably to the lower activity of both
isomers. Accordingly, it should not be surprising that X
registers no activity at 100 AM concentration; the hydro-
phobic fragmental constant (15) for its alkyl chain of four
carbons with one triple bond is 1.371, compared with that
of 1.791 for the corresponding linkage in IX and XI with
one double bond segment, and with that of 2.108 for a
corresponding alkyl chain without any unsaturation. It is
obvious that X is the most polar compound among those
depicted.
For a more extensive discourse on the subject matter the
reader is referred to our most recent work (22).
Supported by National Institutes of Health grants HL-22236 and
HL-25884, and by the Gustavus and Louise Pfeiffer Research Founda-
tion.
Receivedfor publication 18 March 1981.
FUSION AND BIOGENESIS
100(PPP)
50
z0
(n (PRP)
z (Fpp)
4
0(PRP) I I - .k I i I I
,L--L- -- -
-T ow"
EtOH CONTROLADP DONOR:GSQ3 .'M
I -.I I t 1- I -1L
132
REFERENCES
1. Lasslo, A., and P. D. Waller. 1957. 3-(NN-Dialkylcarboxamido)pi-
peridinoalkanes. J. Org. Chem. 22:837-838.
2. Lasslo, A., W. M. Marine, and P. D. Waller. 1956. Substituted
piperidinecarboxamides. J. Org. Chem. 21:958-960.
3. Quintana, R. P., and W. A. Shrader. 1963. Synthesis of selected
amides of mono- and bis(carboxypiperidino)alkanes. J. Pharm. Sci.
52: 1186-1188.
4. Beasley, J. G., R. P. Quintana, and G. G. Nelms. 1964. The effect of
piperidinecarboxamide derivatives on isolated human plasma choli-
nesterase. II. Variations in the amide function. J. Med. Chem.
7:698-701.
5. Quintana, R. P., T. D. Smith, and L. F. Lorenzen. 1965. Synthesis of
carbamoylpiperidine-type cholinesterase inhibitors. J. Pharm. Sci.
54:785-787.
6. Quintana, R. P., and W. R. Smithfield. 1967. Substituted l-benzyl-
3-(N,N-diethylcarbamoyl)piperidine cholinesterase inhibitors. Re-
lationships between molecular constitution, pKa' values and parti-
tion coefficients. J. Med. Chem. 10:1178-1180.
7. Dachary-Prigent, J., J. Dufourcq, C. Lussan, and M. Boisseau. 1979.
Propranolol, chlorpromazine and platelet membrane: a fluorescence
study of the drug - membrane interaction. Thromb. Res. 14:15-
22.
8. Vanderhoek, J., and M. B. Feinstein. 1979. Local anesthetics, chlo-
rpromazine and propranolol inhibit stimulus-activation of phosphol-
ipase-A2 in human platelets. Mol. Pharmacol. 16:171-180.
9. Chap, H. J., R. F. A. Zwaal, and L. L. M. Van Deenen. 1977. Action
of highly purified phospholipases on blood platelets. Evidence for an
asymmetric distribution of phospholipids in the surface membrane.
Biochim. Biophys. Acta. 467:146-164.
10. Marcus, A. J., H. L. Ullman, and L. B. Safier. 1969. Lipid
composition of subcellular particles of human blood platelets. J.
Lipid Res. 10:108-114.
11. Quintana, R. P., A. Lasslo, M. Dugdale, L. L. Goodin, and E. F.
Burkhardt. 1980. Effects of ethanol and of other factors on
ADP-induced aggregation of human blood platelets in vitro.
Thromb. Res. 20:405-415.
12. Quintana, R. P., A. Lasslo, G. S. Queen, and C. M. Baldwin. 1981.
Aspirin analogs with enhanced interfacial activity. J. Colloid
Interface Sci. In press.
13. Lasslo, A., and R. P. Quintana, Editors. 1973. Surface Chemistry
and Dental Integuments. Charles C. Thomas, Springfield, IL.
14. Fisher, R. G., and R. P. Quintana. 1975. Surface-chemical studies
on chlorhexidine and related compounds. II. Interactions with
monomolecular-film systems. J. Dent. Res. 54:25-31.
15. Nys, G. G., and R. F. Rekker. 1974. The concept of hydrophobic
fragmental constants (f-values). II. Extension of its applicability
to the calculation of lipophilicities of aromatic and heteroaromatic
structures. Eur. J. Med. Chem. 9:361-375.
16. Korolkovas, A. 1970. Essentials of Molecular Pharmacology; Back-
ground for Drug Design. Wiley-Interscience, New York; (a) 90,
(b) 65-66.
17. Quintana, R. P. 1964. Relationships between the surface activity and
cholinesterase inhibition of mono- and bis[3-(NN-diethylcarba-
moyl)piperidino]alkanes. J. Pharm. Sci. 53:1221-1223.
18. Quintana, R. P. 1965. Relationships between partition coefficients
and cholinesterase inhibition of carbamoylpiperidinoalkanes. J.
Pharm. Sci. 54:462-463.
19. Narahashi, T., and D. T. Frazier. 1971. Site of action and active
form of local anesthetics. Neurosci. Res. 4:65-99.
20. Strichartz, G. R. 1973. The inhibition of sodium currents in myeli-
nated nerve by quaternary derivatives of lidocaine. J. Gen.
Physiol. 62:37-57.
21. Hille, B. 1977. Local anesthetics: hydrophilic and hydrophobic
pathways for the drug-receptor reaction. J. Gen. Physiol. 69:497-
515.
22. Quintana, R. P., A. Lasslo, M. Dugdale, and L. L. Goodin. 1981.
Relationships between the chemical constitution of carbamoylpi-
peridines and related compounds, and their inhibition of ADP-
induced human blood platelet aggregation. Thromb. Res. 22:665-
680. Cf. Quintana, R. P., A. Lasslo and L. T. Greer. Interaction of
human blood platelet aggregation inhibitors with phospholipid
films. Submitted for publication.
ENVIRONMENTALLY INDUCED REVERSIBLE PROTEIN
TRANSLOCATION ACROSS INNER MITOCHONDRIAL
MEMBRANE
A. WAKSMAN
Centre de Neurochimie du Centre National de la Recherche Scientifique, 67084 Strasbourg Cedex,
France
Four molecular mechanisms account for protein transloca-
tion across biological membranes: translocation via vecto-
rial translation, via vectorial processing, via subunit disso-
ciation, and via environmental induction. Whereas the
first three mechanisms are vectorial, the last one is revers-
ible (1). Fig. 1 describes the general methodology and
observations that led us to the discovery of this last
mechanism.
RESULTS AND DISCUSSION
Externalization of a protein such as aspartate aminotrans-
ferase (AAT) from the inner face of inner mitochondrial
membrane towards intermembranal fluid is shown in Fig.
1, step 1. This step is induced by movement effectors, e.g.,
succinate, fumarate, malate, pyruvate, citrate, phenylsuc-
cinate, a-methylglutamate, etc., at concentrations ranging
from 0 to 50 mM (2). Step 2 shows internalization of
previously externalized AAT upon removal of the move-
ment effector. This was demonstrated by testing the acces-
sibility of the enzyme protein first on the outer face of the
mitoplast (mitochondria from which the outer membrane
was removed), then on the outer face of the corresponding
inverted vesicle, which is equivalent to the inner face of the
mitoplast (step 3). No permeant substrate, controlled
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